Solid Biosciences Inc. (NASDAQ: SLDB) shares traded higher on Thursday. The company announced that it received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for its next-generation Duchenne muscular dystrophy gene therapy candidate known as SGT-003. What To Know: The announcement on Thursday marks the latest development in the progress of Solid Biosciences’ gene therapy candidate.Previously, in mid-November, the company announced that it received IND clearance for SGT-003, pushing the stock higher. However, shares soon pulled back, with the stock largely consolidating…